These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 15990570)

  • 1. Optimal suppression of HIV replication by low-dose hydroxyurea through the combination of antiviral and cytostatic ('virostatic') mechanisms.
    Lori F; Foli A; Groff A; Lova L; Whitman L; Bakare N; Pollard RB; Lisziewicz J
    AIDS; 2005 Jul; 19(11):1173-81. PubMed ID: 15990570
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lowering the dose of hydroxyurea minimizes toxicity and maximizes anti-HIV potency.
    Lori F; Pollard RB; Whitman L; Bakare N; Blick G; Shalit P; Foli A; Peterson D; Tennenberg A; Schrader S; Rashbaum B; Farthing C; Herman D; Norris D; Greiger P; Frank I; Groff A; Lova L; Asmuth D; Lisziewicz J
    AIDS Res Hum Retroviruses; 2005 Apr; 21(4):263-72. PubMed ID: 15943568
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hydroxyurea in combination with didanosine and stavudine in antiretroviral-experienced HIV-infected subjects with a review of the literature.
    Rossero R; Asmuth DM; Grady JJ; McKinsey DS; Green S; Andron L; Pollard RB
    Int J STD AIDS; 2003 May; 14(5):350-5. PubMed ID: 12803944
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hydroxyurea in the treatment of HIV infection: clinical efficacy and safety concerns.
    Lisziewicz J; Foli A; Wainberg M; Lori F
    Drug Saf; 2003; 26(9):605-24. PubMed ID: 12814330
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hydroxyurea plus didanosine as maintenance therapy for HIV-infected patients on long-term successful highly active antiretroviral therapy.
    Barreiro P; de Mendoza C; Camino N; García-Benayas T; Blanco F; Núñez M; González-Lahoz J; Soriano V
    HIV Clin Trials; 2003; 4(6):361-71. PubMed ID: 14628279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pilot study of hydroxyurea in human immunodeficiency virus-infected children receiving didanosine and/or stavudine.
    Kline MW; Calles NR; Simon C; Schwarzwald H
    Pediatr Infect Dis J; 2000 Nov; 19(11):1083-6. PubMed ID: 11099091
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hydroxyurea and didanosine is a more potent combination than hydroxyurea and zidovudine.
    Foli A; Lori F; Maserati R; Tinelli C; Minoli L; Lisziewicz J
    Antivir Ther; 1997 Jan; 2(1):31-8. PubMed ID: 11322264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Absence of viral rebound after treatment of HIV-infected patients with didanosine and hydroxycarbamide.
    Vila J; Nugier F; Barguès G; Vallet T; Peyramond D; Hamedi-Sangsari F; Seigneurin JM
    Lancet; 1997 Aug; 350(9078):635-6. PubMed ID: 9288048
    [No Abstract]   [Full Text] [Related]  

  • 9. Hydroxyurea - new observations.
    Proj Inf Perspect; 1998 Apr; (24):15-7. PubMed ID: 11365714
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Virostatics: a new class of anti-HIV drugs.
    Lori F; Foli A; Kelly LM; Lisziewicz J
    Curr Med Chem; 2007; 14(2):233-41. PubMed ID: 17266582
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is Hydroxyurea for real?
    Mascolini M
    J Int Assoc Physicians AIDS Care; 1998 Aug; 4(8):6-16, 18. PubMed ID: 11365731
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Strategies to improve efficacy and safety of a novel class of antiviral hyper-activation-limiting therapeutic agents: the VS411 model in [corrected] HIV/AIDS.
    De Forni D; Stevens MR; Lori F
    Br J Pharmacol; 2010 Oct; 161(4):830-43. PubMed ID: 20860662
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of primary HIV infection: a pilot study of stavudine and didanosine plus nevirapine with or without hydroxyurea.
    Zala C; Salomón H; Cahn P
    Antivir Ther; 1999; 4 Suppl 3():95-9. PubMed ID: 16021880
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Short-term anti-HIV activity of the combination of didanosine and hydroxyurea.
    Clotet B; Ruiz L; Cabrera C; Ibáñez A; Cañadas MP; Sirera G; Romeu J; Vila J
    Antivir Ther; 1996 Aug; 1(3):189-93. PubMed ID: 11322253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hydroxyurea and didanosine long-term treatment prevents HIV breakthrough and normalizes immune parameters.
    Lori F; Rosenberg E; Lieberman J; Foli A; Maserati R; Seminari E; Alberici F; Walker B; Lisziewicz J
    AIDS Res Hum Retroviruses; 1999 Oct; 15(15):1333-8. PubMed ID: 10515148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interrupting HAART; Hydroxyurea; five+ drug therapy - report from the RIGHT Conference.
    Levin J
    AIDS Treat News; 1999 May; (No 318):3-4. PubMed ID: 11366456
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence of neuropathy in HIV-infected patients on monotherapy versus those on combination therapy with didanosine, stavudine and hydroxyurea.
    Moore RD; Wong WM; Keruly JC; McArthur JC
    AIDS; 2000 Feb; 14(3):273-8. PubMed ID: 10716503
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A placebo-controlled trial of didanosine plus stavudine, with and without hydroxyurea, for HIV infection. The Swiss HIV Cohort Study.
    Rutschmann OT; Opravil M; Iten A; Malinverni R; Vernazza PL; Bucher HC; Bernasconi E; Sudre P; Leduc D; Yerly S; Perrin LH; Hirschel B
    AIDS; 1998 May; 12(8):F71-7. PubMed ID: 9631134
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hydroxyurea in HIV therapy.
    HIV Hotline; 1998 Mar; 8(1):5-7. PubMed ID: 11365359
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune restoration by combination of a cytostatic drug (hydroxyurea) and anti-HIV drugs (didanosine and indinavir).
    Lori F; Jessen H; Lieberman J; Clerici M; Tinelli C; Lisziewicz J
    AIDS Res Hum Retroviruses; 1999 May; 15(7):619-24. PubMed ID: 10331440
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.